No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

For years, Alex­ion’s rare-dis­ease port­fo­lio that cen­tered on C5 in­hibitor Soliris has held its grip on a group of prof­itable ul­tra-rare in­di­ca­tions. But chal­lengers are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.